X0306 4 2021-03-01 0 0001783183 Phathom Pharmaceuticals, Inc. PHAT 0001791412 Nabulsi Azmi C/O PHATHOM PHARMACEUTICALS, INC. 100 CAMPUS DRIVE, SUITE 102 FLORHAM PAK NJ 07932 0 1 0 0 Chief Operating Officer Common Stock 2021-03-01 4 S 0 3825 45.7696 D 805375 I By Trust Common Stock 2021-03-01 4 S 0 1548 46.0549 D 803827 I By Trust Common Stock 2021-03-02 4 S 0 600 44.595 D 803227 I By Trust Common Stock 2021-03-02 4 S 0 4833 46.1576 D 798394 I By Trust Common Stock 2021-03-02 4 S 0 24 46.73 D 798370 I By Trust Common Stock 2021-03-02 4 S 0 1600 45.1722 D 796770 I By Trust Common Stock 2021-03-02 4 S 0 2070 46.2293 D 794700 I By Trust Common Stock 453 D Common Stock 379.87 I By 401(k)Plan All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.96. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.99 to $46.13. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $44.88. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.66 to $46.56. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.76 to $45.55. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.81 to $46.57. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These shares were acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan on January 14, 2021. /s/ Larry Miller, Attorney-in-Fact for Azmi Nabulsi 2021-03-03